MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Circassia Pharmaceuticals PLC Company Profile (LON:CIR)

Consensus Ratings for Circassia Pharmaceuticals PLC (LON:CIR) (?)
Ratings Breakdown: 3 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: GBX 257.50

Analysts' Ratings History for Circassia Pharmaceuticals PLC (LON:CIR)
Show:
DateFirmActionRatingPrice TargetActions
6/21/2016BarclaysInitiated CoverageOverweightGBX 410 -> GBX 170View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016Stifel NicolausDowngradeHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016RBC CapitalDowngradeSector PerformerGBX 430 -> GBX 105View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016JPMorgan Chase & Co.Lower Price TargetOverweightGBX 410 -> GBX 170View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/21/2016Peel HuntDowngradeAddGBX 509 -> GBX 160View Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/20/2016Numis Securities LtdReiterated RatingUnder ReviewView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2015Canaccord GenuityReiterated RatingBuyGBX 325View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/15/2015Shore CapitalReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/26/2015Oriel Securities LtdReiterated RatingAddGBX 320View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/29/2014 forward)
Earnings History for Circassia Pharmaceuticals PLC (LON:CIR)
No earnings announcements for this company have been tracked by MarketBeat.com

Earnings Estimates for Circassia Pharmaceuticals PLC (LON:CIR)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividend History for Circassia Pharmaceuticals PLC (LON:CIR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Circassia Pharmaceuticals PLC (LON:CIR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
9/18/2015Swingland,CharlesInsiderSell754,548GBX 320£2,414,553.60Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Circassia Pharmaceuticals PLC (LON:CIR)
DateHeadline
06/28/16 08:04 AMUS Company expert in Allergy Treatment affirms research fails to find hay fever treatment dose range
06/26/16 06:48 AM[$$] Circassia's blemishes are a reminder of the risks in biotech - [at Financial Times] - Circassia Pharmaceuticals derives its name from a corner of the Ottoman Empire where denizens used an early form of immunotherapy to protect children against bad doses of pox. As a result Circassian slaves ...
06/22/16 07:56 AMCircassia Pharmaceuticals PLC (CIR) Downgraded to "Hold" at Stifel Nicolaus
06/22/16 07:56 AMCircassia's cat allergy drug fails to hit trial targets
06/22/16 07:56 AMCircassia Pharmaceuticals Plc (LON:CIR) price target lowered to GBX160 as covered today by Peel Hunt
06/21/16 03:05 PMFTSE supported by commodity stock rebound
06/21/16 03:05 PMCircassia Pharmaceuticals Plc (LON:CIR) stock price target reduced to GBX0 as announced today by Stifel
06/20/16 09:34 AMCircassia Pharmaceuticals : Reports Failure in Cat Allergy Trial
06/20/16 09:34 AMCircassia Shares Plunge After Trial of Experimental Cat Allergy Drug Fails
06/20/16 09:34 AMCircassia Plunges as Cat-Allergy Treatment Fails Clinical Trial
06/20/16 09:34 AMCircassia Pharmaceuticals: "Dramatic" Placebo Effect In Allergy Study
06/20/16 09:34 AMCircassia's cat allergy treatment fails late-stage trial
06/20/16 09:34 AMWhy are Circassia Pharmaceuticals plc, Royal Bank of Scotland Group plc and McColl's Retail Group plc among today's major movers?
06/20/16 09:34 AMCircassia shares plummet as Phase III trials miss target
06/20/16 09:34 AMCircassia Pharmaceuticals Plc (LON:CIR) price target held steady to GBX0 as announced today by Peel Hunt
06/20/16 09:34 AMCircassia Falls Most Ever as Cat-Allergy Drug Fails in Trial
06/08/16 12:37 PMCircassia Pharmaceuticals Plc – Value Analysis (LONDON:CIR) : June 8, 2016 -
06/07/16 03:40 AMCircassia Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : CIR-GB : June 7, 2016 -
05/26/16 03:36 AMCircassia Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : CIR-GB : May 26, 2016 -
05/25/16 01:26 AMCircassia Initiates Grass Allergy Immunotherapy Registration Study - [at noodls] - Click here to download full press release - Second allergy programme moves into final phase of clinical testing - - Lead programme targeting cat allergy on track to report phase III results Q2 2016 - Oxford, ...
05/25/16 01:16 AMGrass Registration Study Initiation - [at noodls] - Circassia Initiates Grass Allergy Immunotherapy Registration Study Ø Second allergy programme moves into final phase of clinical testing Ø Lead programme targeting cat allergy on track to report phase ...
05/19/16 10:02 AMGrant of awards to Directors - [at noodls] - For immediate release Circassia Pharmaceuticals plc 19 May 2016 In accordance with Disclosure and Transparency Rule 3.1.2 R, Circassia Pharmaceuticals plc announces the grant of options today to its Executive ...
05/17/16 05:00 AMAre Royal Mail plc, AG Barr plc and Circassia Pharmaceuticals plc set to soar by 20%+? -
05/11/16 03:38 AMCircassia Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : CIR-GB : May 11, 2016 -
04/18/16 03:34 AMCircassia Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : CIR-GB : April 18, 2016 -
04/11/16 02:22 PMCircassia Pharmaceuticals Plc – Value Analysis (LONDON:CIR) : April 11, 2016 -
04/08/16 03:34 AMCircassia Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : CIR-GB : April 8, 2016 -
03/11/16 06:07 AMFull Year 2015 Circassia Pharmaceuticals PLC Earnings Release - Time Not Supplied -
02/08/16 01:25 PMChronic Obstructive Pulmonary Disease (COPD) Therapeutics Market - Global Pipeline Review, H2 2015 - Research and Markets - Inc. Chiesi Farmaceutici SpA Circassia Pharmaceuticals Plc Hydra Biosciences, Inc. iCeutica, Inc. InMed Pharmaceuticals Inc. Innate Pharma SA Invion Limited Jiangsu Hansoh Pharmaceutical Co., Ltd. Johnson & Johnson Nostrum Pharmaceuticals, LLC Novabiotics ...
02/01/16 03:37 AMCircassia Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : February 1, 2016 -
01/19/16 03:31 AMCircassia Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : January 19, 2016 -
12/16/15 03:31 AMCircassia Pharmaceuticals Plc breached its 50 day moving average in a Bullish Manner : December 16, 2015 -
12/03/15 03:33 AMCircassia Pharmaceuticals Plc breached its 50 day moving average in a Bearish Manner : December 3, 2015 -
11/24/15 01:43 AMCircassia Announces Positive Outcome of European Decentralised Procedure for Approval of Its Fluticasone Propionate Equivalent of GSK’s FLIXOTIDE® pMDI - [at noodls] - - Product approvable in all reference product strengths - - Successful application based on in vitro demonstration of therapeutic equivalence - Oxford, UK - 24 November 2015: Circassia Pharmaceuticals ...
08/17/15 10:33 AMCircassia’s Extended Offer Period for Aerocrine has Increased Acceptances to 97.2 Percent - [at noodls] - THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, ...
06/03/15 08:00 AMCircassia to Present at EAACI Annual Meeting, Barcelona, Spain, 6-10 June 2015 -
05/30/15 11:00 AMThe surprising success of Britain's university spin-outs -
05/15/15 02:19 AMProsonix to be acquired by Circassia Pharmaceuticals - [at noodls] - Microsoft Word - 150515 Prosonix ENG Press release Leuven / 15 May 2015 QUEST FOR GROWTH Privak, fixed capital investment company established under Belgian Law Leuven, 15 May 2015 Earlier today Circassia ...
05/15/15 01:27 AMGimv portfolio company Prosonix to be acquired by Circassia Pharmaceuticals - [at noodls] - Today, Gimv announced that portfolio company Prosonix (Oxford, UK) is to be acquired by Circassia Pharmaceuticals PLC (www.circassia.co.uk), a clinical-stage specialty biopharmaceutical company listed ...
02/26/15 01:50 AMPreliminary Results for the Year Ended 31 December 2014 - [at noodls] - Click here to download the full 2014 preliminary results statement - Strong clinical progress; Cat-SPIRE phase III study fully recruited - - Robust financial position; fully-funded to bring Cat-SPIRE to ...
02/09/15 09:33 PMCircassia Appoints Lota S Zoth as Non-Executive Director - [at noodls] - Click here to download full press release Oxford, UK - 9 February 2015: Circassia Pharmaceuticals plc ("Circassia" or "the Company"; LSE: CIR), a specialty biopharmaceutical company ...
About Circassia Pharmaceuticals PLC

Circassia Pharmaceuticals PLC logoCircassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates. Its next-generation immunotherapy is in Phase III testing for cat allergy. Its lead asthma treatment targets substitution of GlaxoSmithKline's (GSK's) Flixotide pMDI. It is developing therapies targeting direct substitution of Seretide pMDI and Serevent pMDI. The Company is also developing a range treatment, including a fixed dose triple combination containing an inhaled corticosteroid, long-acting beta agonist and long-acting muscarinic antagonist.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: LON
  • Symbol: CIR
  • CUSIP:
Key Metrics:
  • Previous Close: $1.22
  • 50 Day Moving Average: $233.76
  • 200 Day Moving Average: $267.68
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $263.42M
  • Current Quarter EPS Consensus Estimate: $-23.78 EPS
Additional Links:

            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha